Mereo BioPharma Group Stock (NASDAQ: MREO)

Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BWIN

MREO

This Roper Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday


Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable

Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential

ServiceNow

RCEL

This ServiceNow Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group PLC

Press Releases

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Financing

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Earnings

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

RARE

Absci

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

aTyr Pharma

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Heron Therapeutics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Comments

Mereo BioPharma Group

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga